AccuGenomics Inc is pleased to announce that it has joined the FNIH Biomarkers Consortium focused on Measurable residual disease in acute myeloid leukemia (MRD in AML). We look forward to our participation in advancing the accuracy of targeted NGS testing of liquid biopsy samples.
As a disruptive precision diagnostics technology company, AccuGenomics’s mission is to improve the accuracy and performance of clinical sequencing testing for better patient outcomes. The rapid pace of innovation in NGS diagnostics continues to push the limits of detection for low abundance biomarkers, increasing the need to demonstrate the analytical performance of Companion Diagnostic (CDx) tests for patients and healthcare providers. We create internal standards for targeted NGS assays that reduce uncertainty and give clinicians and patients the accuracy in data to make confident medical decisions by eliminating false positive and false negative results, allowing the true underlying biology to be seen. We design and manufacture internal spike in standards that enable accurate detection of low abundance biomarkers from liquid biopsy or other sample types (can be any target, any platform, and any sample type). We improve the true limit of detection (LOD) for NGS assays so even rare variants can be identified so that the molecular markers of cancer can be detected earlier, even from liquid biopsy samples.
The Foundation for the National Institutes of Health (FNIH) is a not-for-profit charitable organization chartered by Congress to create and manage alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Biomarkers Consortium at FNIH is the preeminent public-private partnership focused on identifying, developing, and qualifying biomarkers that accelerate therapeutics and improve clinical care.
